We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Research interviews
-
1. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
-
2. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
4. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
5. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
6. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
7. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
8. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
9. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
10. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
12. Cancer vaccines
- Dr. Elias Sayour
-
13. The regulation of cell therapy
- Prof. Moutih Rafei
-
14. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
15. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
16. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
-
17. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
18. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
19. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
20. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
21. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
23. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
24. MassBank development and future
- Dr. Emma L. Schymanski
-
25. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
26. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
27. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
28. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Clinical interviews
-
29. Predicting asthma exacerbations using machine learning models
- Dr. Nestor Molfino
-
30. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
32. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
33. Characterizing barriers to care in migraine
- Prof. Dawn C. Buse
-
34. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
-
36. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
37. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Sebastian Kobold
-
38. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
39. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
-
40. Combating the HIV epidemic
- Prof. William Blattner
-
41. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
42. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
43. Pediatric cancer testing
- Prof. Joshua Schiffman
-
44. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
-
45. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
-
46. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
47. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
Topics Covered
- Addressing current clinical trial challenges with new technologies
- Digital health technologies and biomarkers in clinical development
- Benefits and challenges of digital health technologies in trials
- Impact of technologies on patient experience and engagement
- How can the pharmaceutical industry expand digital health technology adoption
Biography
Rinol Alaj is Senior Director, Head of Digital Health Technologies at Regeneron. His professional focus is centered around integrated innovation, design thinking, and clinical operation with 15+ years of experience in the startup and pharma industries. A savvy, results-oriented leader, Mr. Alaj has proven success in transforming and building eCOA organizations from the ground up. He received his undergraduate and graduate degrees in computer science from New Jersey Institute of Technology, where he also went on to earn his MBA. Mr. Alaj is currently pursuing his Master’s in Public Health – Epidemiology and Biostats program at CUNY Graduate School of Public Health and Health Policy.
Talk Citation
Alaj, R. (2025, May 29). Integrating novel digital health technologies into clinical trials [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 2, 2025, from https://doi.org/10.69645/RDXV1725.Export Citation (RIS)
Publication History
- Published on May 29, 2025
Financial Disclosures
- Mr. Rinol Alaj has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: In recent years, we
have seen an increasing number of
digital health
technologies being
integrated into clinical trials.
These technologies
aim to improve
data collection as well
as patient engagement.
We're joined today
by Rinol Alaj,
head of digital health
technologies at
Regeneron to discuss
these developments.
Rinol, thank you very much
for joining us today.
Mr. Alaj: Thank
you for inviting me.
Interviewer: What are some
of the current challenges with
clinical trials that these
technologies are
trying to address?
Mr. Alaj: Historically,
clinical trials are
complex so over the past decade,
drug developers have recognized
the need to adopt and
progress the design
and execution of
the clinical trials
in order to increase the
speed of the drug discovery.
Specifically, one
critical challenge with
clinical trials is how
we're collecting the data.
During the clinical
trial, researchers
collect data in many
different ways.
Examples, if you look
at the clinical data,
such as vitals, imaging,
and laboratory tests.
These are collected at
doctor's office or
laboratory, which
basically limits our ability to
collect continuous
real-time data.
On the other hand, if we
look at the quality of
life measurements or
patient-reported outcomes,
which are subjective
measures where patients
basically report how
they function and feel.
These measures can introduce
variability bias because
they are often done at
a specific point
in time and also
requires patients to
recall how they feel.
This is specifically an
area of focus throughout
my career, specifically
at my previous company